

**For Immediate Release**

25<sup>th</sup> June 2007

## **PLETHORA SOLUTIONS HOLDINGS PLC**

### **Clinical Update – PSD597 for interstitial cystitis**

#### **Completion of Recruitment in PSD597 Clinical Study**

**Plethora Solutions Holdings PLC** ("Plethora", AIM : PLE), the specialist developer of products for the treatment and management of urological disorders is pleased to announce the completion of patient recruitment into its Phase II clinical study of PSD597 for the treatment of interstitial cystitis (IC). The study is a double-blind placebo controlled study with patients recruited from over 20 centres in the USA and Canada. The objective of the study is to confirm both immediate and sustained relief of the symptoms of interstitial cystitis. The outcome of the trial will be known later in 2007.

Plethora has previously reported encouraging clinical pilot data from two studies in both volunteers and IC sufferers which demonstrated that PSD597 immediately and effectively reduced the pain of interstitial cystitis. This effect was maintained for a considerable period of time thereafter in the absence of obtrusive side effects.

PSD597 is a proprietary formulation of a marketed analgesic product which is applied into the bladder using a technique suitable for both out-patient clinics and home administration. The proprietary formulation affords new patent protection and the product is covered by an extensive existing long-term safety package that provides a potential fast track to market.

Interstitial cystitis (IC) is a chronic, debilitating condition characterised by bladder and pelvic pain and increased urinary frequency and urgency which has a major impact on patient quality of life. IC is consistently associated with chronic pelvic pain (CPP). A UK study of almost 25,000 women found the prevalence of CPP to be 38%, which is comparable to the reported prevalence of migraine (37%) and back pain (41%). Current treatments for IC and CPP are limited in their effectiveness.

A second PSD597 trial to explore the potential benefits of the product providing pain relief during the many hundreds of thousands of minor urological surgical procedures performed every year is also nearing full enrolment and will also report later in 2007.

#### **Dr Steven Powell, CEO of Plethora commented:**

"Interstitial Cystitis is an area where there are limited effective treatment options despite the large number of patients who are affected by the disease either on a regular or sporadic basis. We believe that PSD597 has potential to address a clear medical need and represents a significant market opportunity. We look forward to updating shareholders on the progress of this exciting new product later this year."

-Ends-

**For further information contact:**

**Plethora Solutions**

*Steven Powell*

**Tel : 020 7269 8630**

**City/Financial Enquiries**

**Maitland**

*Brian Hudspith/Liz Morley*

**Tel: 020 7379 5151**

**Scientific/Trade Press Enquiries**

**DeFacto Communications**

*Richard Anderson*

**Tel: 020 7861 3838**

**About Plethora:**

Plethora is focused on the development and marketing of products for the treatment of urological disorders. The Company has products in clinical development for the treatment of overactive bladder, stress urinary incontinence, interstitial cystitis, gynaecological pain, erectile dysfunction and premature ejaculation. In January 2006, Plethora acquired Minneapolis (Mn) based Timm Medical Technologies Inc which markets products for the treatment of erectile dysfunction (ED) to urology clinics through a US-based specialty sales team. The Company is headquartered in the UK and is listed on the London Stock Exchange (AIM:PLE) Further information is available at **[www.plethorasolutions.co.uk](http://www.plethorasolutions.co.uk)**